Golden
Cellerant Therapeutics

Cellerant Therapeutics

A biotechnology company that develops treatments for cancer and hematologic conditions

Cellerant Therapeutics is a clinical stage biotechnology company based in San Carlos, California that develops cell- and antibody-based immunotherapies for hematological malignancies and other blood-related disorders. Cellerant's pipeline includes Romyelocel-L (CLT-008) and two antibody drug conjugates (ADC), CLT030 and CSC012-ADC.

Romyelocel-L is an off-the-shelf universal cell therapy intended to prevent infections during neutropenia, a severe side effect of many chemotherapy regimens, particularly for acute myeloid leukemia (AML) and other blood related disorders. It has the potential to significantly reduce the risk of serious infection. Romyelocel-L is manufactured from hematopoietic stem cells obtained from screened and tested healthy donors. The stem cells are then expanded and differentiated into myeloid progenitor cells (MPCs) and is then cryopreserved. The FDA has granted Romyelocel-L Regenerative Medicine Advance Therapy (RMAT) designation for the prevention of neutropenia in AML. Cellerant plans to launch Phase 3 trials in 2019. The therapy is also being tested for efficacy to treat neutropenia in acute radiation syndrome (ARS) and increase tolerance of organ transplants.

CLT030, which is in development and is expected to enter Phase 1 clinical trials in 2019, is an ADC with a highly potent, DNA-binding payload, for the treatment of AML. It targets C-type lectin molecules (CLEC12A), a cell surface marker highly expressed on leukemic stem cells. It has shown promising efficacy in animal models.

CSC012 is a lead Interleukin-1 receptor accessory protein (IL1RAP) targeting antibody that has been selected and conjugated with a series of linker payloads to generate the antibody drug conjugate, CSC012-ADC. In vitro and in vivo results have demonstrated that it is a potent ADC and an excellent candidate for further development as a targeted treatment for AML.

Timeline

People

Name
Role
Related Golden topics

Angelica Rusan

Employee

Antoun Nabhan

Investor

Daphne Fong

Employee

Eric Morse

Employee

Esther Danenberg

Employee

Gautam Banik

VP Manufacturing & Process Sciences

Gautam Banik

Employee

Irving L. Weissman

Founder

Jagath Reddy Junutula

VP Antibody Discovery & Development

Ram Mandalam

President & CEO

Rodney Young

CFO

Sean Givens

Employee

Sean Healy

Employee

Timothy C. Fong

Employee

Vanessa Love Van Pell

Employee

William Reed

Employee

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References